SOUTH SAN FRANCISCO, Calif.(BUSINESS WIRE)
Allogene Therapeutics, Inc., a clinical-stage biotechnology company
pioneering the development of allogeneic CAR T (AlloCAR T?) therapies
for cancer, today announced the appointment of Deborah (Debbie) M.
Messemer to the Company's Board of Directors. Ms. Messemer has more than
30 years of experience providing financial expertise to public and
private companies and was the Managing Partner of KPMG's Bay Area and
Northwest region until her recent retirement.
Debbie is a seasoned executive with deep financial and audit
experience. She also served as the senior account executive for some of
KPMG's largest and most prominent clients, said Arie Belldegrun, M.D.,
FACS, Executive Chairman and Co-Founder of Allogene. As Allogene
continues to progress, Debbie's financial expertise and applied
understanding of our stage of growth will play an important role on our
Ms. Messemer, a certified public accountant (CPA), joined KPMG LLP, the
U.S. member firm of KPMG International, in 1982 and was admitted into
partnership in 1995. As Managing Partner for the Bay Area and Northwest
region, she was responsible for leading over 3,000 team members in 10
offices across all functions, including audit, tax and advisory. Ms.
Messemer spent the majority of her career in KPMG's audit practice as an
audit engagement partner serving public and private clients in a variety
of industry sectors. In addition to audit signing responsibilities, Ms.
Messemer has significant experience in SEC filings, due diligence,
initial public offerings, mergers and acquisitions, and internal
controls over financial reporting.
I was drawn to this opportunity to serve on Allogene's Board of
Directors because of its life-changing mission and its world-class
management team that has demonstrated the ability to innovate
cutting-edge cancer therapies, said Ms. Messemer.
Ms. Messemer was honored as the Financial Woman of the Year by the
Financial Women of San Francisco (FWSF) in 2016 and was named as one of
the Bay Area's Most Influential Women in Business by the San Francisco
Ms. Messemer is a member of the National Association of Corporate
Directors (NACD) and of the San Francisco Chapter of Women Corporate
Directors (WCD). She has served extensively on non-profit and advisory
boards including the Bay Area Council, the San Francisco Committee on
Jobs, the California Chamber of Commerce, the San Francisco Chamber of
Commerce, the UC Berkeley Fisher Center Policy Advisory Board, San
Francisco Ballet, and Posse. She is a member of the International
Women's Forum and Leadership San Francisco, Class of 2001. She received
a bachelor's degree in accounting from the University of Texas at
Allogene is advancing its AlloCAR T? cell portfolio, which includes
rights to 16 preclinical CAR T cell therapy targets and U.S. rights to
UCART19, an AlloCAR T? cell therapy candidate that is being developed
for the treatment of CD19-expressing hematological malignancies. In
partnership with Servier, UCART19 is in Phase 1 development for the
treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the development of
allogeneic chimeric antigen receptor T cell (AlloCAR T?) therapies for
cancer. Led by a world-class management team with significant experience
in cell therapy, Allogene is developing a pipeline of off-the-shelf
CAR T cell therapy candidates with the goal of delivering readily
available cell therapy faster, more reliably and at greater scale to
AlloCAR T? cell therapies are engineered from cells of healthy donors,
which is intended to allow for creation of inventory for on demand use
in patients. This approach is designed to eliminate the need to create
personalized therapy from a patient's own cells, simplify manufacturing,
and reduce the time patients must wait for CAR T cell treatment. The
Allogene portfolio includes rights to 16 pre-clinical CAR T cell therapy
targets and UCART19, an AlloCAR T? therapy candidate currently in Phase
1 development for the treatment of relapsed/refractory acute
lymphoblastic leukemia (ALL). For more information, please visit www.allogene.com, and
follow @AllogeneTx on Twitter and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180927005228/en/
Allogene Media/Investor Contact:
Chief Communications Officer
Source: Allogene Therapeutics, Inc.